Botanix Pharmaceuticals Ltd has released a press release.
FDA Mid-Cycle Review Meeting Successfully Completed
Filed with ASX ·
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Botanix Pharmaceuticals Limited on 6ix
Earlier from Botanix Pharmaceuticals
- Half Yearly Report and Accounts
- Press Article Correction
- Appendix 4C - Quarterly
- Confirmation Sofpironium Bromide NDA Formally Under Review
- Placement Completion and Results of Share Purchase Plan
Later from Botanix Pharmaceuticals
- Botanix Raises A$10 million via Institutional Placement
- Botanix successfully completes A$10m Placement
- March 2023 Quarterly Activities Report and Appendix 4C
- New Territory Licensed for Sofpironium Bromide with Kaken
- Botanix Pharmaceuticals: The West Australian | Botanix Pharmaceuticals secures $12.5m via an institutional placement
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals